The Wegovy 1mg pen: what it is, what it does, and what comes next

The 1mg pen is not a maintenance dose — and that matters

A question our prescribers hear fairly often is whether someone can simply stay on the 1mg pen long-term if they feel fine at that level. It is an understandable thought: the nausea has settled, the routine feels manageable, so why push further? The honest answer is that the 1mg dose is part of a scheduled escalation designed to get you to the dose where the medicine does its real work, not a clinical destination in its own right.

The licensed titration pathway for Wegovy runs from 0.25mg up through 0.5mg, then 1mg, then 1.7mg, arriving at the 2.4mg maintenance dose — and with the MHRA's 2026 approval of a 7.2mg pen, there is now a higher ceiling for those who tolerate and need it. The full Wegovy dose schedule explains each step and its purpose.

Staying at 1mg without clinical reason means accepting substantially less average weight reduction than trials recorded at the maintenance dose. According to the STEP 1 trial results reported on the NHS semaglutide medicines page, average weight loss across the study ran to around 15% over 68 weeks, and that was achieved at 2.4mg, not 1mg. The 1mg pen's job is to steady your system for what comes next.

How the 1mg pen fits into the semaglutide schedule: the actual mechanics

Semaglutide works as a GLP-1 receptor agonist: it mimics a gut hormone that signals fullness to the brain, slows the rate at which the stomach empties, and reduces appetite. At lower doses, these effects are present but blunted. The incremental escalation exists because introducing the full therapeutic effect immediately would cause significant gastrointestinal side effects for most people.

By the time a patient reaches the 1mg pen, they have typically been on treatment for about eight weeks. The injection site, rotation routine, and storage habit (the pen sitting in the fridge door alongside everyday items) should feel unremarkable by now. That familiarity is deliberate: it reduces the cognitive load so the focus can shift to how the body is responding.

The move from 1mg to the 1.7mg pen comes next, again after roughly four weeks if tolerated. The prescriber reviews each step; it is not automatic. Some people spend longer at 1mg if gastrointestinal symptoms have been persistent. That is a clinical call, and one worth discussing openly rather than quietly stopping.

Missed doses, timing adjustments, or decisions about pausing escalation should always go back to your prescriber and the Patient Information Leaflet, those decisions depend on individual history.

Side effects at the 1mg stage and what the evidence says

Gastrointestinal effects are the most commonly reported: nausea, loose stools, constipation, indigestion, and occasionally vomiting. Most people find these are more noticeable in the first days after each dose increase than at a steady dose. By 1mg, many patients have already experienced their sharpest adjustment, the step from 0.5mg to 1mg tends to produce milder reactions than the earlier steps for most people, though not everyone.

NICE's recommendation for semaglutide (TA875) notes that stopping treatment should be considered if less than 5% weight loss is achieved after six months at the maintenance dose. This reinforces that 1mg is not the dose at which continued treatment is evaluated; it is a step on the way.

More serious but less frequent effects to be aware of include symptoms of pancreatitis (severe, persistent stomach pain that spreads to the back, with or without vomiting) which requires prompt medical attention. Any suspected side effects can be reported through the MHRA Yellow Card scheme. Wegovy carries a Black Triangle (▼) designation, meaning reports contribute to ongoing post-market safety monitoring.

For a broader look at the evidence behind the treatment, our Wegovy overview covers the trial background and what the clinical data shows.

What happens after 1mg: planning the next step with a prescriber

Moving from 1mg toward the 1.7mg and then the 2.4mg maintenance pen is where most of the clinically meaningful weight loss occurs. For patients for whom 2.4mg is well tolerated and more reduction is needed, the 7.2mg dose (approved by the MHRA in April 2026) represents the highest currently licensed option in the UK.

If you are managing your treatment privately and want to understand the full titration map before your next review, our guide to Wegovy pen dosing sets out each stage clearly. For questions about what treatment might cost at each stage, a cost comparison for Wegovy in the UK gives honest context on private pricing without the hidden extras some providers tack on.

Clinical suitability is always the starting point. If you have not yet had a consultation, or you want a second opinion on your current titration, speaking to our prescribers is the straightforward next step. A real clinician reviews your answers the same day, not software, not a queue.